Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia.

Autor: Loghavi S; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Wei Q; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Ravandi F; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Quesada AE; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Routbort MJ; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Hu S; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Toruner GA; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Wang SA; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Wang W; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Miranda RN; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Li S; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Xu J; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., DiNardo CD; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Daver N; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Kadia TM; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Issa GC; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Kantarjian HM; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Medeiros LJ; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Tang G; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Oct; Vol. 99 (10), pp. 1959-1968. Date of Electronic Publication: 2024 Jul 17.

Aggressive Mediastinal Lymphomas.

Autor: Wang X; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Wang W; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Vega F; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Quesada AE; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: aquesada@mdanderson.org.

Publikováno v: Seminars in diagnostic pathology [Semin Diagn Pathol] 2024 May; Vol. 41 (3), pp. 125-139. Date of Electronic Publication: 2021 Jun 16.

Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm.

Autor: He J; Division of Pediatrics., Garcia MB; Division of Pediatrics., Connors JS; Division of Pediatrics., Nuñez CA; Division of Pediatrics., Quesada AE; Department of Hematopathology., Gibson A; Division of Pediatrics., Roth M; Division of Pediatrics., Cuglievan B; Division of Pediatrics., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., McCall D; Division of Pediatrics.

Publikováno v: Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2023 Nov 01; Vol. 45 (8), pp. e1001-e1004. Date of Electronic Publication: 2023 Sep 04.

Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies.

Autor: Cuglievan B; Division of Pediatrics, Department of Pediatric Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Bcuglievan@mdanderson.org., Connors J; Division of Pediatrics, Department of Pediatric Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., He J; Division of Pediatrics, Department of Pediatric Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Khazal S; Division of Pediatrics, Department of Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yedururi S; Division of Radiology, Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dai J; Division of Internal Medicine, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garces S; Division of Pathology, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Quesada AE; Division of Pathology, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Roth M; Division of Pediatrics, Department of Pediatric Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia M; Division of Pediatrics, Department of Pediatric Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., McCall D; Division of Pediatrics, Department of Pediatric Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gibson A; Division of Pediatrics, Department of Pediatric Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ragoonanan D; Division of Pediatrics, Department of Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Petropoulos D; Division of Pediatrics, Department of Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tewari P; Division of Pediatrics, Department of Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nunez C; Division of Pediatrics, Department of Pediatric Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mahadeo KM; Division of Pediatric Transplantation and Cellular Therapy, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA., Tasian SK; Division of Oncology and Center for Childhood Cancer Research, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Lamble AJ; Division of Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA, USA., Pawlowska A; Division of Pediatric Hematology/Oncology, and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, CA, USA., Hammond D; Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maiti A; Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haddad FG; Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Senapati J; Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver N; Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gangat N; Department of Hematology, Mayo Clinic, Rochester, MN, USA., Konopleva M; Department of Oncology, Montefiore Einstein Cancer Center, Bronx, NY, USA., Meshinchi S; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Pemmaraju N; Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: Leukemia [Leukemia] 2023 Sep; Vol. 37 (9), pp. 1767-1778. Date of Electronic Publication: 2023 Jul 14.

Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies.

Autor: Jelloul FZ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: fjelloul@mdanderson.org., Quesada AE; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yang RK; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Li S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang W; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Xu J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tang G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yin CC; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fang H; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., El Hussein S; Department of Pathology, University of Rochester Medical Center, Rochester, New York., Khoury J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bassett RL; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Manasanch EE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Orlowski RZ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Qazilbash MH; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Patel KP; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Medeiros LJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lin P; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: peilin@mdanderson.org.

Publikováno v: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2023 Jun; Vol. 36 (6), pp. 100166. Date of Electronic Publication: 2023 Mar 27.